Literature DB >> 25093310

[Antiretroviral therapy].

Amrei von Braun1, Hansjakob Furrer2, Manuel Battegay3, Alexandra Calmy4, Matthias Cavassini5, Pietro Vernazza6, Enos Bernasconi7, Rainer Weber1, Huldrych F Günthard1.   

Abstract

Antiretroviral therapy to treat HIV, as we know it today, is nothing less than a huge success story in modern medical history. What used to be an almost certain death-sentence was transformed into a very manageable chronic disease by means of highly efficient und mostly well tolerated drugs. Today, HIV-infected patients treated according to international recommendations have a very good chance to outgo the negative effects of HIV-1 and are therefore able to reach an almost normal life expectancy. Furthermore, patients successfully treated with antiretroviral drugs are no longer infectious, which is an essential aspect of global strategies to overcome the pandemic. Nevertheless, due to the complexity of HIV, physicians treating patients with antiretroviral therapy require profound knowledge of aspects such as viral resistance mechanisms and immune reconstitution, as well as drug-toxicity und drug-drug-interactions. Many other aspects such as long-term side-effects of antiretroviral drugs are still unknown. Strict adherence to treatment is of utmost importance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25093310     DOI: 10.1024/0040-5930/a000538

Source DB:  PubMed          Journal:  Ther Umsch        ISSN: 0040-5930


  2 in total

1.  Predictors of immunodeficiency-related death in a cohort of low-income people living with HIV: a competing risks survival analysis.

Authors:  M F P M Albuquerque; D N Alves; C C Bresani Salvi; J D L Batista; R A A Ximenes; D B Miranda-Filho; H R L Melo; M Maruza; U R Montarroyos
Journal:  Epidemiol Infect       Date:  2017-01-09       Impact factor: 4.434

2.  Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro.

Authors:  Peipei Xu; Yingchun Wang; Zhao Qin; Lisha Qiu; Min Zhang; Yunlong Huang; Jialin C Zheng
Journal:  J Neuroimmune Pharmacol       Date:  2017-07-22       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.